Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEPS Trial: Dapagliflozin for Repaired Tetralogy of Fallot
NCT06668389Phase 4Recruiting
- Sponsor
- The University of Hong Kong
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of dapagliflozin in tetralogy of Fallot (TOF) (2 arms), sponsored by The University of Hong Kong. Primary endpoint: Maximal oxygen uptake at 3 months. Started May 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
tetralogy of Fallot (TOF)
Beyond the preview
Go deeper on NCT06668389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668389.